Corbus Pharmaceuticals Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Net Income (Loss) Available to Common Stockholders, Basic of -$5.35 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2016-11-10
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$5.35M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2016-06-30 was -$4.19M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2016-03-31 was -$2.89M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-12-31 was -$2.50M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2015 was -$8.85M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2014 was -$2.54M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2016-09-30 | -$5.35M 10-Q · filed 2016-11-10 | -$9.54M derived: sum of 2 quarters · filed 2016-11-10 | -$12.43M 10-Q · filed 2016-11-10 | -$14.93M derived: sum of 4 quarters · filed 2016-11-10 |
| 2016-06-30 | -$4.19M 10-Q · filed 2016-08-12 | -$7.08M 10-Q · filed 2016-08-12 | -$9.58M derived: sum of 3 quarters · filed 2016-08-12 | -$11.83M derived: sum of 4 quarters · filed 2016-11-10 |
| 2016-03-31 | -$2.89M 10-Q · filed 2016-05-13 | -$5.39M derived: sum of 2 quarters · filed 2016-05-13 | -$7.64M derived: sum of 3 quarters · filed 2016-11-10 | -$10.21M derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28 | -$4.75M derived: sum of 2 quarters · filed 2016-11-10 | -$7.32M derived: sum of 3 quarters · filed 2016-11-10 | -$8.85M 10-K · filed 2016-03-28 |
| 2015-09-30 | -$2.25M 10-Q · filed 2016-11-10 | -$4.82M derived: sum of 2 quarters · filed 2016-11-10 | -$6.35M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | -$2.56M 10-Q · filed 2016-08-12 | -$4.10M 10-Q · filed 2016-08-12 | ||
| 2015-03-31 | -$1.54M 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | -$2.54M 10-K · filed 2016-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |